Disease-modifying anti-rheumatic drug therapy in rheumatoid arthritis patients : optimizing therapy and risk prediction /
Files
(Published version)
Date
2023
Authors
Daraghmeh, Dala
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
thesis
Citation
Statement of Responsibility
Conference Name
Abstract
The research in this thesis is focused on advancing the precision use of disease modifying anti-rheumatic drugs in rheumatoid arthritis (RA) patients. The first part of the project is focused on developing a novel bioanalytical assay for methotrexate (MTX) and administration of MTX as a loading dose to hasten the onset of MTX response. Measuring MTX using various blood matrices has the potential to inform a better understand MTX pharmacokinetics and guide novel MTX dose regimens. In the second part of the project, I used data sourced from industry sponsored clinical trials to predict therapeutic outcomes to RA treatments. This allows personalized treatment decisions that can improve patient outcomes. Through developing personalized treatment strategies, patients can take a more precise drug/dose to achieve an optimal outcome while minimizing side effects.
School/Discipline
University of South Australia. UniSA Clinical and Health Sciences.
UniSA Clinical and Health Sciences
UniSA Clinical and Health Sciences
Dissertation Note
Thesis (PhD(Pharmacology))--University of South Australia, 2023.
Provenance
Copyright 2023 Dala Daraghmeh
Description
1 ethesis (xxii, 307 pages) :
colour illustrations.
Includes bibliographical references (pages 291-306)
colour illustrations.
Includes bibliographical references (pages 291-306)
Access Status
506 0#$fstar $2Unrestricted online access